These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12001649)

  • 21. NOS knockouts and neuroprotection.
    Grünewald T; Beal MF
    Nat Med; 1999 Dec; 5(12):1354-5. PubMed ID: 10581072
    [No Abstract]   [Full Text] [Related]  

  • 22. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.
    Kalkonde YV; Morgan WW; Sigala J; Maffi SK; Condello C; Kuziel W; Ahuja SS; Ahuja SK
    Brain Res; 2007 Jan; 1128(1):1-11. PubMed ID: 17126305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New insights into the pathophysiology of cobalamin deficiency.
    Scalabrino G; Peracchi M
    Trends Mol Med; 2006 Jun; 12(6):247-54. PubMed ID: 16690356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neural degeneration in Parkinson's disease.
    Riederer P; Reichmann H; Janetzky B; Sian J; Lesch KP; Lange KW; Double KL; Nagatsu T; Gerlach M
    Adv Neurol; 2001; 86():125-36. PubMed ID: 11553969
    [No Abstract]   [Full Text] [Related]  

  • 25. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.
    Luchtman DW; Shao D; Song C
    Physiol Behav; 2009 Aug; 98(1-2):130-8. PubMed ID: 19410592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice.
    Vivacqua G; Biagioni F; Yu S; Casini A; Bucci D; D'Este L; Fornai F
    J Chem Neuroanat; 2012 Jul; 44(2):76-85. PubMed ID: 22580273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The structure and mechanism of neurotransmitter receptors. Implications for the structure and function of the central nervous system.
    Strange PG
    Biochem J; 1988 Jan; 249(2):309-18. PubMed ID: 2893605
    [No Abstract]   [Full Text] [Related]  

  • 28. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
    Teng X; Sakai T; Liu L; Sakai R; Kaji R; Fukui K
    J Neurochem; 2006 May; 97(4):1126-35. PubMed ID: 16686692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease.
    Taylor JM; Main BS; Crack PJ
    Neurochem Int; 2013 Apr; 62(5):803-19. PubMed ID: 23291248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroinflammation in Parkinson's disease.
    Hirsch EC; Vyas S; Hunot S
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S210-2. PubMed ID: 22166438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Changes in brain level of neurotransmitters].
    Kanazawa I
    Nihon Naika Gakkai Zasshi; 1991 Jul; 80(7):1148-52. PubMed ID: 1680945
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H; Kato T; Arawaka S
    Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.
    Sriram K; Matheson JM; Benkovic SA; Miller DB; Luster MI; O'Callaghan JP
    FASEB J; 2006 Apr; 20(6):670-82. PubMed ID: 16581975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Out FOXing Parkinson disease: where development meets neurodegeneration.
    Wexler EM; Geschwind DH
    PLoS Biol; 2007 Dec; 5(12):e334. PubMed ID: 18092892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Volume transmission.
    Ridet I; Privat A
    Trends Neurosci; 2000 Feb; 23(2):58-9. PubMed ID: 10652543
    [No Abstract]   [Full Text] [Related]  

  • 36. Neural degeneration and the transport of neurotransmitters.
    Edwards RH
    Ann Neurol; 1993 Nov; 34(5):638-45. PubMed ID: 7902065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.
    Kurkowska-Jastrzebska I; Bałkowiec-Iskra E; Ciesielska A; Joniec I; Cudna A; Zaremba MM; Członkowski A; Członkowska A
    Int Immunopharmacol; 2009 Jun; 9(6):781-91. PubMed ID: 19286483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The MPTP tale: pathway to prevention of Parkinson's disease?
    Williams A; Waring R
    Br J Hosp Med; 1993 May 19-Jun 1; 49(10):716-9. PubMed ID: 8324592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation in Parkinson's disease.
    Wüllner U; Klockgether T
    J Neurol; 2003 Feb; 250 Suppl 1():I35-8. PubMed ID: 12761634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory processes in complex regional pain syndromes.
    Hauser J; Hsu B; Nader ND
    Immunol Invest; 2013; 42(4):263-72. PubMed ID: 23883195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.